观看

摘要: 1306

PDF (英语): 519

Cited-by

1. Xu C, Chen Y, Yu Q, Song J, Jin Y, Gao X. Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential. Frontiers in Pharmacology. 2023;14. doi: 10.3389/fphar.2023.1243286
2. Eksi OB, Guler A, Akdeniz M, Atalay P, Hamurcu Z, Aydin O. Development of silver-based hybrid nanoparticles loaded with eEF2 K-siRNA and quercetin against triple-negative breast cancer. Drug Delivery and Translational Research. 2025;. doi: 10.1007/s13346-025-01860-6
3. Xu S, Yin S, Wang L, Zhong H, Wang H, Yu H. Insights into emerging mechanisms of ferroptosis: new regulators for cancer therapeutics. Cell Biology and Toxicology. 2025;41(1). doi: 10.1007/s10565-025-10010-0
4. You P, Tang L, Zhu Y, Tian Y. Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway. Aging. 2023;15(10):4411. doi: 10.18632/aging.204744
5. Ge A, He Q, Zhao D, Li Y, Chen J, Deng Y, et al. Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis. Journal of Cellular and Molecular Medicine. 2024;28(1). doi: 10.1111/jcmm.18044
6. Mangalpady SS, Peña-Corona SI, Borbolla-Jiménez F, Kaverikana R, Shetty S, Shet VB, et al. Arnicolide D: a multi-targeted anticancer sesquiterpene lactone—preclinical efficacy and mechanistic insights. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(9):6317. doi: 10.1007/s00210-024-03095-7